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Hypoxia-inducible factor 2α (HIF-2α) plays a pivotal role in the balancing of oxygen requirements throughout the
body. The protein is a transcription factor that modulates the expression of a wide array of genes and, in turn, con-
trols several key processes including energy metabolism, erythropoiesis and angiogenesis. We describe here the
identification of two cases of familial erythrocytosis associated with heterozygous HIF2A missense mutations,
namely Ile533Val and Gly537Arg. Ile533Val is a novel mutation and represents the genetic HIF2A change nearest
to Pro-531, the primary hydroxyl acceptor residue, so far identified. The Gly537Arg missense mutation has already
been described in familial erythrocytosis. However, our patient is the only described case of a de novo HIF2Amuta-
tion associated with the development of congenital polycythemia. Functional in vivo studies, based on exogenous
expression of hybrid HIF-2α transcription factors, indicated that these genetic alterations lead to the stabilization
of HIF-2α protein. All the identified polycythemic subjects with HIF2A mutations show serum erythropoietin in
the normal range, independently of the hematocrit values and phlebotomy frequency. The erythroid precursors
obtained from the peripheral blood of patients showed an altered phenotype, including an increased rate of
growth and a modified expression of some HIF-2α target genes. These results suggest the novel proposal that poly-
cythemia observed in subjects with HIF2Amutations might also be due to primary changes in hematopoietic cells
and not only secondary to increased erythropoietin levels.
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ABSTRACT
Introduction 
Regulation of oxygen homeostasis is critical to survival.
Accordingly, eukaryotes have developed molecular mecha-
nism(s) for the maintenance of proper oxygen tissue levels. A
major physiological consequence of hypoxia is the enhanced
renal synthesis of erythropoietin (EPO) and the increase of
serum EPO. In turn, the cytokine stimulates red cell produc-
tion restoring the oxygen supply to tissues.1,2
EPO is produced by kidney interstitial fibroblasts in close
association with peritubular capillary and tubular epithelial
cells.3,4 The cytokine is also synthesized in the perisinusoidal
cells in the liver.5 However, while liver synthesis predomi-
nates in the fetal and perinatal periods, renal production is
clearly predominant during adulthood. The hypoxia-depen-
dent up-regulation of renal EPO production is almost exclu-
sively due to the activation of EPO gene transcription.3,4 The
protein is then rapidly modified and released in the serum.
Erythroid precursors at specific stages of differentiation
express high levels of EPO receptor (EPOR) whose engage-
ment results in increased red cell production.6-8
Induction of EPO gene transcription by hypoxia has led to
the discovery of the transcription factor hypoxia-inducible
factor (HIF) and the molecular pathways that allow the mod-
ulation of HIF levels by oxygen levels.9 HIF consists of two
subunits, HIF-α and HIF-β, whose nuclear heterodimeriza-
tion results in the active form. Only the levels of HIF-α,
which exists in two isoforms HIF-1α and HIF-2α, are regulat-
ed by oxygen content.10-13 In particular, normoxia induces the
ubiquitin-mediated degradation of HIF-α. Conversely, cellu-
lar HIF-α isoforms levels are increased by low O2 partial pres-
sure.
The ubiquitination of HIF-α requires a previous prolyl-4-
hydroxylation that commits the transcription factor to the
interaction with an E3 ubiquitin-protein ligase.14-17 The E3 com-
plex is formed by various proteins including the von Hippel-
Lindau protein (VHL), elongins B and C, cullin 2, and RBX1.14-17
Three prolyl hydroxylases (PHD 1-3), identified in mammalian
cells, use O2 as a substrate to generate 4-hydroxyproline at spe-
cific prolyl residues of HIF-α.18,19
The primary site of hydroxylation of HIF-2α is Pro-531,
which corresponds to proline 564 in HIF-1α.20,21 The hydroxy -
proline represents a specific degron that allows HIF-2α
recognition by VHL.22 Under normoxic conditions, the
activities of PHD (mainly PHD2) and VHL maintain the
HIF-α (both HIF-1α and HIF-2α) content at almost unde-
tectable levels.23 Conversely, hypoxic conditions rapidly
decrease HIF-α prolyl hydroxylation thus allowing the
accumulation of the transcription factor.23 In the nucleus,
HIF-α associates with HIF-β forming an active complex
endowed with transcriptional activity.24 The HIF-α/HIF-β
heterodimer binds to target consensus sequences in the
regulatory regions of several hundreds of genes and acti-
vates their expression.25-27 
HIF target genes are involved in the control of a plethora
of molecular processes including the regulation of cell
growth and differentiation, the activation of apoptosis and
the modulation of cell movement and migration.25-27
Accordingly, several complex physiological and patholog-
ical events are regulated by HIF levels, such as hormone
regulation, energy metabolism, angiogenic signaling, vaso-
motor regulation, matrix and barrier functions, transport
and virus-related genes.25-27 Although still debated, various
data suggest that HIF-1α/HIF-β and HIF-2α/HIF-β regulate
different genes and modulate, in part, distinct processes.28
Recent studies have identified congenital erythrocyto-
sis-associated mutations in the genes that encode for VHL,
PHD2 and HIF-2α.29-41 The genetic changes embrace
homozygous or compound heterozygous mutations of
the VHL gene, heterozygous PHD2 gene changes, and het-
erozygous mutations of the HIF2A gene.29-41 Specific HIF2A
and PHD2 haplotypes have also been associated with
adaptation to high altitudes in Tibetans, confirming the
central role of these genes in the hypoxic response.42-44
Interestingly, no mutation of HIF1A has been reported so
far.35,45 Mechanistically, PHD2 and VHL mutations lead to
loss of function of the respective proteins, while HIF2A
mutations probably lead to a gain of function of HIF-2α.29-
41 A small number of subjects affected by inherited HIF2A
mutations (Pro534Leu, Met535Val, Met535Ile,
Met535Thr, Gly537Trp, Gly537Arg, Asp539Glu,
Phe540Leu) in heterozygosity have been described. These
patients show a dominant erythrocytosis and increased or
inappropriately normal EPO serum levels.34-41 In some
cases, the patients present a history of thrombosis or pul-
monary hypertension.35 Increased serum EPO is supposed
to be the cause of erythrocytosis in these patients. In addi-
tion to these patients, three cases of somatic gain-of-func-
tion HIF2A mutations (Ala530Thr, Ala530Val, Phe374Tyr)
associated with paraganglioma and polycythemia as well
as with increased serum EPO have been reported.46-48
In the present report, we identify two HIF2A mutations
associated with erythrocytosis and analyze the effect of
the genetic change on transcription factor stability and
activity. One change is a de novomutation, a condition that
represents the first direct genetic proof that HIF2A muta-
tions might be the cause of hereditary erythrocytosis. We
also describe, for the first time, the features of red cell pro-
genitors prepared from the patients bearing HIF2A genetic
changes. 
Methods
Patients
We analyzed a series of 75 patients with sporadic, apparently
congenital or familial erythrocytosis. All patients gave informed
written consent on entering the study, which had been approved
by the Ethics Committee of the Second University of Naples, in
accordance with the Declaration of Helsinki.
Case reports
Patient 1 is an asymptomatic 15-year old Italian male who pre-
sented with an increased hemoglobin (Hb) of 17.3 g/dL, hemat-
ocrit (Hct) of 0.52, white cell count of 9.3x109/L, and a platelet
count of 245x109/L during routine blood tests at 9 years of age.
The oxygen dissociation curve and abdominal ultrasound were
both normal. His serum EPO was 6.3 mU/mL (reference range,
3.7-31 mU/mL). He has no history of thrombosis or pulmonary
hypertension and no family history of erythrocytosis. His last EPO
measurement (July 2012) was 8.7 mU/mL (Hb, 17.8 g/dL; Hct,
0.53). Both parents have normal Hb and Hct levels. 
Patient 2 is a 30-year old Italian male who presented with
headache, dizziness and fatigue. He had a Hb of 19.1 g/dL and a
Hct of 0.55 with normal white cell and platelet counts. His spleen
was normal on ultrasound. He was a light smoker with no history
of either thromboembolic events or pulmonary hypertension. He
did not use any medications. Arterial blood gas analysis showed
normal oxygen saturation and p50 values. His EPO level was 18
mU/mL (reference range, 3.7-31 mU/mL).  His carboxyhemoglo-
bin value was 1.6% (normal range, <1.5%). He has been managed
for the past 15 years by regular venesection and remains well at
the age of 45 years. His last EPO level was 25 mU/mL (August
2012; Hb, 17.1 g/dL; Hct, 0.51). His asymptomatic 16-year old
daughter also had an erythrocytosis  (Hb of 18.0 g/dL, Hct of 0.53)
with EPO level near to the low limit of the normal range (6.1
mU/mL).
Mutation screening 
Genomic DNA were collected at diagnosis from all patients and
relatives.
Erythroid precursor cultures
Liquid cultures of peripheral erythroid precursors were prepared
by employing peripheral blood CD34+ cells as a source of progen-
itors.8
Quantitative polymerase chain reaction analysis
cDNA was prepared from patients’ mRNA from erythroid pre-
cursors with an I-Script kit (Bio-Rad). Real-time polymerase chain
reaction (PCR) was performed for adrenomedullin (ADM), N-myc
downstream regulated gene 1 (NDRG1), vascular endothelial
growth factor (VEGF) and transferrin receptor (TFR) genes, in
accordance with the manufacturers’ instructions. The reactions
were run on an ABI 7300 real-time PCR system (Applied
Biosystems). Assays were performed in triplicate. We used the 2-
ΔΔCt method to analyze the data obtained.
Plasmids
A PCR product spanning the human HIF-2α oxygen-dependent
degradation (ODD) region (amino acids 404-569) was cloned into
the EcoRI site of pM3-VP16 (Clontech) to obtain one-hybrid con-
structs harboring a N-terminal GAL4 DNA-binding domain and a
C-terminal VP16 transactivation domain. The plasmid was mutat-
ed at specific residues as reported in the text. Human PHD expres-
sion vectors have been described earlier.49,50
In vitro prolyl-4-hydroxylation assays
Enzymatic activities of recombinant PHD1, PHD2 and PHD3 on
HIF-2α peptide mutants were determined by an His6- and thiore-
doxin-tagged pVHL/elongin B/elongin C (VBC) binding assay,
essentially as described elsewhere.49,50
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Luciferase assays
The experiments were performed essentially as reported by
Wirthner et al.49 and Stiehl et al.50
More details of the design and methods of this study are avail-
able in the Online Supplementary Appendix.
Results
Clinical and genetic characterization of patients
A cohort of 75 patients affected by congenital erythro-
cytosis were investigated for the presence of mutations in
the JAK2, EPOR, VHL, PHD1, PHD2, PHD3, HIF1A and
HIF2A genes. In detail, the following regions were
sequenced: JAK2 (exons 12 and 14), EPOR (exons 7 and 8),
VHL (entire coding sequence), PHD1 (exons 1-5), PHD2
(exons 1-4), PHD3 (exons 1-3), HIF1A (exons 9, 12 and 15),
and HIF2A (exon 12). Two patients (1 and 2) were found
to have two different HIF2A mutations. 
Patient 1 is heterozygous for a c.1609 G>A mutation,
which predicts replacement of glycine with arginine at
residue 537 (Gly537Arg) (Figure 1). This mutation has
been previously reported by us and others.35-37 The
sequence of exon 12 of the HIF2A gene of both the parents
of patient 1 did not evidence the Gly537Arg change.
Genetic analysis confirmed paternity with an index of
99% (data not reported). Of note, this patient is the first case
described in literature in which the HIF2A alteration
appeared as a de novo mutation. The patient’s serum EPO
level was repeatedly found to be near the lower value of
the reference range. 
Patient 2 is heterozygous for a novel A to G change at
c.1597 (c.1597A>G), corresponding to an Ile533Val muta-
tion (Figure 2). The change creates a BmsF1 restriction site
(Figure 3). The alteration was also found in the patient’s
son confirming the family history of erythrocytosis. To
test whether this mutation was a single-nucleotide poly-
morphism, a control panel of 200 DNA samples was
screened by means of BsmF1 digestion. No case of muta-
tion was identified. Serum EPO levels were within the ref-
erence range in patient 2 and his affected son.
Effect of HIF-2α mutations on protein metabolism
The detected mutations share two key features with
previously described pathogenetic HIF2A changes. First,
both the mutations are present in heterozygosity. Second,
they affect residues that closely follow the main and pri-
mary site of prolyl hydroxylation in HIF-2α (i.e. Pro-531).
However, the occurrence of HIF-2α-dependent familial
erythrocytosis with normal EPO serum levels might cast
some doubts on the effect of mutations on HIF-2α stabili-
ty and, in turn, on the molecular mechanism(s) of the dis-
ease.
Previously reported in vitro experiments suggested that
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Figure 1. Identification of the Arg537Gly mutation in the HIF2A gene.
(A) Detection of the c.1609 G>A (Gly537Arg) mutation by PCR-direct
sequencing. PCR-direct sequencing was performed on total peripher-
al blood DNA using specific primers to amplify exon 12 of the HIF2A
gene. Sequencing detected a heterozygous G to A change at base
1609 in patient 1, as indicated by the arrow, as compared to the
wild-type sequence (upper panel). Nucleotides 1604–1617 are
shown. Bases are as follows: G black; A green; T red; C, blue.  (B) The
pedigree of the family of patient 1 is shown. Squares represent male
family members, circles represent female family members, and
solid symbols represent family members with erythrocytosis; the
genotype is shown under the symbol. 
Figure 2. Identification of the Val533Ile mutation in the HIF2A gene.
(A) Detection of the c.1597 A>G (Ile 533Val) mutation by PCR-direct
sequencing. PCR-direct sequencing was performed on total peripher-
al blood DNA using specific primers to amplify exon 12. Sequencing
detected a heterozygous A to G change at base 1597 in patient 2, as
indicated by the arrow, as compared to the wild-type sequence
(upper panel). Nucleotides 1589–1603 are shown. Bases are as fol-
lows: G, black; A,  green; T,  red; C,  blue. (B) The pedigree of the fam-
ily of patient 2 is shown. Squares represent male family members,
circles represent female family members, and solid symbols repre-
sent family members with erythrocytosis; genotypes are shown
under each symbol.
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the Gly537Arg mutation affects the interaction of HIF-2α
peptides with PHD2 and VHL as well as their ability to act
as hydroxyl acceptors.39 Thus, we performed experiments
to evaluate the ability of different PHD (PHD1-3) to
hydroxylate Pro-531 on peptides including Gly537Arg or
Ile533Val changes. Therefore, wild-type (Figure 4A) and
mutated biotin-HIF-2α-derived peptides (amino acids 523-
542) were bound to NeutrAvidin-coated 96-well plates.
The peptides were hydroxylated by the addition of
recombinant GST-PHD (PHD1, PHD2 and PHD3). The
degree of hydroxylation was evaluated by the binding of
a recombinant thioredoxin-tagged protein complex
formed by VHL/elongin B/elongin C (VBC) to the hydrox-
ylated peptide. The amount of bound VBC was then esti-
mated by an enzyme-linked immunosorbent assay
(ELISA) including rabbit antithioredoxin antibodies and
secondary horseradish peroxidase-coupled anti-rabbit
antibodies. Thus, the method allows the assessment of
PHD activity on a putative substrate peptide by quantify-
ing the binding to the hydroxylated peptide of the VBC
complex (and not simply to VHL protein). 
As shown in Figure 4B, biotinylated peptides (from HIF-
1α and HIF-2α) containing increasing proportions of syn-
thetically generated hydroxyproline residue demonstrate a
direct proportionality between the absorbance at 405 nm
and the percentage of peptide hydroxylation. Addition of
recombinant active PHD1, PHD2 and PHD3 to wild-type
peptides also increased VBC binding (Figure 4C). Finally,
since we preferred to use oxidation-insensitive peptides in
which methionine 535 is substituted by alanine, we con-
firmed that this change did not affect the efficiency of
hydroxylation by the three PHD (Figure 4D).
Next, we evaluated the hydroxylation of five different
peptides, encompassing the region from 523 to 542, which
carry the following changes: Gly537Arg, Ile533Val,
Gly537Ala, Gly537Trp and Ala535Val (Figure 5A). We also
tested a wild-type peptide (as a positive normal control)
and the Pro531Ala (P531A) mutant peptide (as the nega-
tive control). In the absence of a recombinant PHD, no
Pro-531 hydroxylation occurs (Figure 5B). In contrast, in
the presence of all PHD isoforms, VBC binding to the
wild-type peptide is approximately 8- to 10-fold higher
than to the P531A mutant peptide (Figure 5C). None of the
five HIF-2α mutations analyzed affected the efficiency of
PHD-dependent hydroxylation, except the repeatedly
observed diminished PHD3-dependent hydroxylation of
the Gly537Arg mutant (Figure 5C).
To investigate whether HIF2A mutations might affect
the in vivo stability of HIF-2α protein, Hek293 cells were
transfected with an expression vector encoding a mutant
fusion protein formed by the GAL4 DNA-binding domain,
the HIF-2α ODD (amino acids 404-569) domain and the
VP16 transactivation domain. The cells were co-transfect-
ed with a GAL4-responsive reporter plasmid containing
the firefly luciferase gene under control of the E1b promot-
er and five GAL4 response elements. Whereas the wild-
type ODD domain decreased fusion protein-dependent
luciferase activity under normoxic conditions, double-
mutation of the ODD region (by replacing the two
hydroxyl-acceptors Pro-531 and Pro-564 with alanine)
strongly induced fusion protein activity (Figure 5D).
Interestingly, the fold increase was similar to that induced
by the proline double mutation when one of the three
indicated mutations was introduced into the ODD
domain, suggesting that these mutations led to compara-
ble protein stabilization (Figure 5D). 
Following overexpression of PHD 1 to 3, a strong reduc-
tion of luciferase activity was observed in the wild-type
control sample (Figure 5D). Conversely, no decrease of
luciferase activity was observed in the samples transfected
with ODD lacking the two pivotal prolines. In contrast to
the normoxic basal conditions, overexpression of any of
the three PHD led to a partial inhibition of luciferase activ-
ity mediated by the three mutant fusion proteins, most
likely due to partial inhibition of their VHL-mediated
degradation (Figure 5D). Of note, diminished proline
hydroxylation of Gly537Arg by PHD3 could not be con-
firmed by the transfection experiments.
Effect of HIF-2α mutations on erythroid 
precursor phenotype
As reported above, the serum EPO levels did not
increase in the identified polycythemic patients with
HIF2A mutations. Conversely, EPO concentrations were
frequently near the lower end of the range and would not,
therefore, explain the erythrocytosis in these patients.
Since HIF-2αmight affect the expression of a significant
number of genes modifying cell phenotypes, we won-
dered whether erythroid precursors of patients showed
phenotypic alterations. The expression of a number of
HIF-2α target genes, i.e. ADM, NDRG1, VEGF and TFR
was examined by quantitative PCR analysis. As shown in
Figure 6A, the Gly537Arg and Ile533Val mutations
induced a significant increase in transcript levels of ADM,
NDRG1, VEGF and TFR genes in circulating erythroid pro-
genitors when compared to the levels in corresponding
cells from control subjects. 
Previous experiments demonstrated that peripheral ery-
throid progenitors of congenital polycythemic subjects are
hypersensitive to EPO through an as of yet unknown
HIF2A gene mutations in congenital erythrocytosis
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Figure 3. Identification of the Ile533Val mutation by BsmF1 diges-
tion. Lymphocytic cDNA from a control (lane 2), patient 2 (lanes 1
and 4), his daughter (lane 3) and his affected son (lane 5) were
amplified using primers localized in HIF2A exon 12. The amplified
materials were not digested (lane 1) or digested with BmsF1 (lanes
2-5). The unrestricted PCR product is 868 bp long. BmsF1 digestion
results in two fragments of 517 and 351 bp in the absence of the
Val533Ile mutation (lanes 2 and 3). The presence of the c1597 A>G
mutation creates a second BmsF1 restriction site in the 351 bp frag-
ment and the formation of two further fragments of 206 and 145 bp
each (lanes 4 and 5). MW, molecular weight.
BmsF1 digestion
MW 1 2 3 4 5
IIe533Val
868
517
351
206
145
underlying mechanism. This feature is particularly evident
at EPO concentrations lower than 1 U/mL. Thus, to inves-
tigate the phenotypic features of erythroid precursors of
our patients, we characterized the in vitro proliferation of
these precursors. In these experiments, EPO was
employed at a low concentration (0.1 U/mL) to identify a
putative hyper-responsivity to the cytokine. As shown in
Figure 6B, erythroid precursors from our patients showed
an increased growth rate when compared to a control, as
determined by direct cell counting. 
To confirm the findings obtained by reverse transcrip-
tase PCR, vascular endothelial growth factor and soluble
transferrin receptor concentrations were determined in the
growth medium of the erythroid precursors after 7 days
(i.e. from day 0 to day 7) and 14 days (i.e. from day 8 to
day 14) of culture. As shown in Figure 6C, protein data
correlated with the mRNA data shown in Figure 6A.
Soluble transferrin receptor could be detected only after 14
days of culture, in accordance with the known observa-
tion that only mature erythroid precursors (CFU-E cells)
synthesize transferrin receptor.
Discussion
In the present study a novel HIF2A mutation (Ile533Val)
occurring in patient with congenital erythrocytosis has been
characterized. Moreover, we identified a polycythemic sub-
ject in whom the presence of a de novo HIF2A genetic
change (Gly537Arg) is associated with the development of
the disease. The HIF2A-dependent erythrocytosic patients
did not have increased serum levels of EPO. The levels of
S. Perrotta et al.
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Figure 4. HIF-2α peptide
hydroxylation. (A)
Sequences of HIF-1α and
HIF-2α peptides employed
in the VBC binding assay
for proline hydroxylation.
The arrow shows the
hydroxyacceptor proline.
(B) Different known per-
centage of hydroxyproline
HIF-α peptides (depicted
in panel A) were subjected
to a VBC binding assay as
described in the Methods
section. (C) Wild-type and
mutant HIF-1α and HIF-2α
peptides (P564A and
P531A, respectively) were
subjected to in vitro
hydroxylation by recombi-
nant purified PHD iso-
forms. (D) Wild-type and
mutant HIF-1α and HIF-2α
peptides (Met531Ala
mutation) were subjected
to in vitro hydroxylation by
recombinant purified PHD
isoforms. 
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the cytokine were, conversely, repeatedly found near the
lower end of the physiological range, independently of
phlebotomy. These findings suggest that HIF2A mutations
might induce erythrocytosis, at least in the described cases,
by affecting processes independent of increased EPO pro-
duction. Accordingly, we found that HIF2A genetic changes
affect the phenotype of erythroid precursors. 
The novel genetic HIF2A change identified, namely
Ile533Val mutation, represents the hereditary alteration
closest to Pro-531 reported so far.33 Although the missense
is clearly a conservative substitution, i.e. a bulky
hydrophobic amino acid is substituted by another large
hydrophobic residue, the change produces significant
functional defects. Intriguingly, Ile-533 is conserved in
HIF2A gene mutations in congenital erythrocytosis
haematologica | 2013; 98(10) 1629
Figure 5. Functional effects of HIF-2α mutations. (A) Sequences of wild-type and mutant HIF-2α peptides employed. (B) HIF-2α peptides (depict-
ed in panel A) and containing the indicated point mutations were used for a VBC binding assay in the absence of recombinant PHD isoforms.
(C) The same HIF-2α peptides were used for the VBC binding assay following hydroxylation by the recombinant PHD as indicated. While wild-
type peptides were efficiently hydroxylated by all PHD, the HIF-2α G456R mutation showed reduced hydroxylation specifically by PHD3 by
approximately 40%. (D) Subconfluent Hek293 cultures were co-transfected with pGRE5xE1bluc, 250 ng of pM3-HIF-2α (amino acids 404-569)
and 200 ng of the respective PHD expression construct or empty expression vector. Different mutants of pM3-HIF-2α were used, as reported in
the figure, including: the wild-type (WT) form; a form mutated in both the hydroxylable proline residues (PP/AA) and three forms encoding
G537W, G537R and I533V mutants. pRL-SV40 was used to normalize for transfection efficiency. Twenty-four hours post-transfection, cultures
were equally distributed into 12-well plates and grown for an additional 24 h in 20% oxygen. Cells were subjected to a dual luciferase assay.
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HIF-2α proteins from mammalian species, human HIF-1α
and HIF-3α, as well as HIF-2α proteins from chicken, frog,
and zebrafish. The importance of this residue is further
highlighted by X-ray crystallographic studies on the con-
figuration of an HIF-1α peptide bound to VHL and the co-
crystal structure of HIF-1α (556-574):PHD2.51-53 These
structures show that Ile 566 in HIF-1α (which corresponds
to Ile-533 of HIF-2α) is localized in one of two regions that
are predicted to make essential contacts with VHL and
PHD2 (residues 528-533 and residues 539-542).
Our study also describes the first identified case of a de
novo HIF2A mutation associated with the development of
congenital polycythemia. The genetic change reported,
glycine 537 to arginine, occurs in seven out of the 19 cases
of HIF2A mutations (5 out of 12 families) associated with
congenital polycythemia so far described (including
ours).35-37 As mentioned in the Introduction, a further change
at Gly-537 (Gly537Trp) has been identified in three
patients (1 family), allowing us to consider Gly-537 as a
hot spot in the HIF2A gene.34
Following the identification of the erythrocytosis-asso-
ciated Gly537Arg and Ile533Val HIF2A gene mutations,
we functionally characterized the two mutant proteins.
Functional studies on the Gly537Arg HIF-2α mutant have
been published previously, although employing distinct
experimental approaches.37,39 Initially, we used peptides
encompassing the mutations identified (Gly537Arg and
Ile533Val), and compared the results with peptides show-
ing a different change in Gly-537 (namely, Gly537Ala) or
HIF2A mutations reported by others (i.e., Gly537Trp and
Met535Val) and associated with familial erythrocytosis.
By means of an ELISA-based test, originally developed and
employed in HIF-1α studies,49,50 we investigated both the
PHD-dependent hydroxylation of the peptides and their
subsequent binding to a VHL-containing complex. No dif-
ferences were found between the wild-type and the
mutated peptides. Previous studies employed peptides
similar to those used in the present study (including
Gly537Trp and Gly537Arg mutations) to evaluate either
binding to PHD2 or the interaction with VHL.34,39 These
analyses showed that the mutations remarkably reduce
the peptide/PHD2 association and the peptide/VHL inter-
action. Although we cannot definitely explain the bases of
the different results, we may suggest that they could
derive from the use of distinct approaches. For instance,
binding between the peptides and PHD2 was investigated
by co-immunoprecipitation but peptide hydroxylation by
PHD2 was not analyzed.39 Moreover, to investigate the
binding between VHL and the hydroxylated peptides, we
used the complex formed by VHL, elongin B and elongin
C and not recombinant VHL alone (as previously done by
others). Although the different interaction studies could
explain the difference between our results and those
reported previously, they cannot explain the difference in
the hydroxylation observed in our studies. A critical reap-
praisal of the findings obtained from in vitro approaches
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Figure 6. Effects of HIF-2α mutations on peripheral erythroid precur-
sor phenotypes. (A) Results of real-time PCR assays. Total RNA was
prepared from primary cultures of peripheral erythroid precursors.
RNA was reverse transcribed and the concentrations of transcripts of
the vascular endothelial growth factor gene (VEGF), adrenomedullin
gene (ADM), N-myc downstream regulated gene 1 (NDRG1), and
transferrin receptor gene (TFR) were determined by the real-time
PCR. The values obtained were reported as fold-increase over the
transcript concentrations from primary cultures of erythroid precur-
sors from control subjects. Means from three separate experiments
are shown. T bars indicate standard deviations. (B) Growth rate of pri-
mary cultures of peripheral erythroid precursors. Proliferation was
determined by cell counting. The content of erythropoietin in the cell
culture medium was 100 mU/mL. Means from three separate exper-
iments are shown. T bars indicate standard deviations. (C) Content of
vascular endothelial growth factor (VEGF) and soluble transferrin
receptor (sTFR) in the growth media of primary cultures of peripheral
erythroid precursors. The media of the first and second weeks of
incubation were collected and VEGF and sTFR levels were deter-
mined by ELISA. Means from three separate experiments are shown.
T bars indicate standard deviations.
A B
C
3.0
2.5
2.0
1.5
1.0
0.5
1.2
1.0
0.8
0.6
0.4
0.2
600
500
400
300
200
100
1600
1400
1200
1000
800
600
400
200
IIe533Val
Gly537Arg
Cont
IIe533Val
Gly537Arg
VEGF sTFR
VEGF ADM NDRG1 TFR
7 14
Days
7 14
Days
0 2 4 6 8 10 12 14
Days
Healthy subject
IIe533Val HIF-2α
Gly537Arg HIF-2α
m
RN
A 
le
ve
l (
fo
ld
 re
la
tiv
e 
to
 c
on
tro
l)
pg
/m
L 
gr
ow
th
 m
ed
iu
m
μg
/m
L 
gr
ow
th
 m
ed
iu
m
Ce
lls
 (%
 o
f d
ay
 0
)
and based on the use of peptides seems necessary to deter-
mine the usefulness of these methodologies for investigat-
ing the functional consequences of HIF-2α mutations.
The in vivo experiments, on the other hand, clearly show
that the identified HIF-2α mutants are more stable than
the wild-type counterpart. This was demonstrated either
in cells overexpressing all PHD or in unmodified cells with
endogenous HIFα proline hydroxylases only. These results
demonstrated that the identified genetic alterations result
in increased transcriptional activity of the mutated pro-
tein. 
A further observation of this study is that no increase of
serum EPO was observed in the polycythemic patients
identified here.34-41 Similar data were reported in other
studies on HIF2A-dependent polycythemias although
scarce attention has been paid to this finding.37-44 So far
seven patients, including the case reported here, have been
found to have the Gly537Arg HIF2A mutation. Three
patients belong to the same family. Two of them had very
high EPO levels (about 2000 mU/mL) while the third had
normal EPO levels (26 mU/mL).37 The EPO concentrations
in three other subjects (from 3 families) ranged from 60
mU/mL to >200 mU/mL.36 Our patient has an EPO level of
about 6-18 mU/mL. There is, therefore, no apparent inter-
play between a specific HIF2A change and EPO level. Two
hypotheses might explain the absence of correlation
between genetic status and cytokine level. One is the dif-
ferent genetic background of subjects and the other is the
age of patients (and their treatments, including phle-
botomies). 
Since variation of serum EPO content might not explain
the polycythemic phenotype of our patients, we hypoth-
esized that erythrocytosis might be due (at least in part) to
intrinsic alterations of erythroid precursors and/or other
components of the hematopoietic niche. We found that
peripheral erythroid precursors from the HIF2A-depen-
dent polycythemic patients showed an increased rate of
growth in vitrowhen compared to the normal counterpart. 
An increased hypersensitivity to EPO has also been
observed in the erythroid progenitors from patients with
congenital polycythemia due to the Chuvashian VHL
(R200W) mutation.29,54 Recently, it has been suggested
that this could be due to impaired  degradation of phos-
phorylated JAK2 related to altered binding of VHL
R200W with SOCS.55
Moreover, a noticeable up-regulation of the expression
of some HIF-2α target genes was also evidenced in these
cells, confirming observations reported in other cell sys-
tems showing HIF-2α mutated protein.34,38,39
Two different approaches confirmed the last finding,
namely quantitative PCR and the direct evaluation of HIF-
2α-regulated protein released by the erythroid precursors
in the culture medium. Collectively, these data demon-
strate, for the first time, that erythroid precursors from
patients with congenital erythrocytosis due to HIF2A gain-
of-function mutations have a different phenotype with
respect to the normal counterpart. This finding suggests,
as also indicated by recent data,56 that HIF-2α is essential
for excessive erythropoiesis in defects of the hypoxia sens-
ing pathway.
In conclusion, we identified a novel HIF2A mutation
responsible for hereditary erythrocytosis and the occur-
rence of a de novo HIF2A change associated with develop-
ment of the disease. Moreover, we suggest that the func-
tional effects of the mutations should be evaluated mainly
by in vivo experiments. Finally, we believe that the erythro-
cytosis due to HIF2A genetic changes is not simply a con-
sequence of increased EPO but is probably due to more
general effects on different cell phenotypes including ery-
throid precursor cells.
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SUPPLEMENTARY METHODS 
 
Patients 
All patients had an elevated hematocrit (Hct), with normal leukocyte and platelets 
counts, and serum EPO level normal or inappropriately high for their Hct.  
 
Materials 
Human VEGF Quantikine ELISA Kits TFR were obtained by R&D Systems 
(Minneapolis, MN 55413, USA). sTfR Human ELISA (soluble Transferrin Receptor) 
was from Biovendor (Brno, The Czech Republic). All the peptides employed were 
synthesized by GenScript Corporation (Scotch Plain, NJ 07076.0855, USA). 
 
Mutation screening  
All patients were screened for VHL, EPOR, PHD1, PHD2, PHD3, HIF1A, HIF2A 
gene mutations.1  
 
Erythroid precursor cultures 
The details of preparation procedure, culture conditions and cell characterization are 
reported in ref 1.  
 
Plasmids 
pGRE5xE1 plasmid is a GAL4-responsive reporter plasmid containing the firefly 
luciferase gene under control of E1b promoter and five GAL4 response elements 
(kind gift of D. Peet, Adelaide, Australia).  
 
In vitro prolyl 4-hydroxylation assays 
Briefly, biotinylated human wild-type or mutant HIF-1α- or HIF-2α-derived peptides 
(HIF-1α, amino acids 555–573; HIF-2α, amino acids 523–542) were bound to 
NeutrAvidin-coated 96-well plates (Thermo Scientific, Rockford, IL USA 61101). 
Recombinant GST-PDH1, GST-PHD2 or GST-PHD3 enzymatic assays were carried 
out for 1 h at room temperature. Bound VBC complex was detected by rabbit anti-
thioredoxin antibodies and secondary horseradish peroxidase-coupled anti-rabbit 
antibodies (Sigma) using the 3,3,5,5-tetramethylbenzidine substrate kit (Thermo 
Scientific). The peroxidase reaction was stopped by adding H2SO4, and absorbance 
was determined at 450 nm in a microplate reader. Inter-assay comparability was 
guaranteed by calibration of each experiment to an internal standard curve using 
hydroxyproline-containing peptides.2, 3  
 
Luciferase assays 
Subconfluent 6-wells of HEK293 cell cultures were co-transfected with 125 ng of 
pGRE5xE1bluc, 250 ng of wild-type or mutated pM3-HIF2α (404-569, wild-type or 
mutated sequence) and 200 ng of the respective PHD expression construct or empty 
expression vector. Mastermixes contained 3.5 ng pRL-SV40 to normalize for 
transfection efficiency. 24 hours post transfection, cultures were equally distributed 
onto 12-well plates and grown for additional 24 hours at 20% oxygen. Cells were 
subjected to dual luciferase assay as recommended by the manufacturer.2, 3   	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